NBTXR3

DEVICE4 trials

Sponsors

Nanobiotix, M.D. Anderson Cancer Center

Conditions

Adult Soft Tissue SarcomaImmunotherapyLocally-Advanced Non-Small Cell Lung CancerMetastasis From Malignant Melanoma of Skin (Disorder)Metastasis From Malignant Tumor of Bladder (Disorder)Metastasis From Malignant Tumor of CervixMetastasis From Malignant Tumor of LiverMetastatic NSCLC

Phase 1

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity

CompletedNCT01433068

NanobiotixAdult Soft Tissue Sarcoma

Start: 2011-10-31End: 2015-02-28Updated: 2020-10-06

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Active, not recruitingNCT03589339

NanobiotixImmunotherapy, Metastasis From Malignant Melanoma of Skin (Disorder), Metastasis From Malignant Tumor of Bladder (Disorder) +8

Start: 2019-01-16End: 2027-08-30Target: 145Updated: 2025-10-24

NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer

RecruitingNCT07224152

M.D. Anderson Cancer CenterLocally-Advanced Non-Small Cell Lung Cancer

Start: 2026-03-27End: 2030-08-30Target: 40Updated: 2026-09-18

Phase 2

NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall

CompletedNCT02379845

NanobiotixAdult Soft Tissue Sarcoma

Start: 2015-03-03End: 2020-09-20Updated: 2021-04-06

Related Papers

Reirradiation with NBTXR3/SBRT in combination with nivolumab or pembrolizumab for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma (HNSCC) in the phase I trial study 1100.

Journal of Clinical Oncology2026-05-27

Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC

Future Oncology2025-05-058 citations

Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.

Journal of Clinical Oncology2024-06-014 citations

1092 Induction of lysosomal membrane permeabilization by radiotherapy-activated NBTXR3 nanoparticles

Regular and Young Investigator Award Abstracts2023-10-31

Abstract PR05: Changing the radiation and immune-oncology paradigm in patients with head and neck squamous cell carcinoma (HNSCC) with the radioenhancer NBTXR3: From bench to bedside

Clinical Cancer Research2023-09-15

Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.

Journal of Clinical Oncology2023-06-017 citations

Abstract 2414: Early biological impacts of radiotherapy-activated NBTXR3 nanoparticles

Cancer Research2023-04-04

684 NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers: results from an ongoing dose escalation phase I trial (Study 1100)

Regular and Young Investigator Award Abstracts2022-11-016 citations

682 Changing the radiation and immune-oncology paradigm with the radioenhancer NBTXR3: overcoming resistance to anti-PD-1 blockade from the bench to the clinic

Regular and Young Investigator Award Abstracts2022-11-01

Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma.

2022-07-1625 citations

NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial.

2021-11-01

Overcoming Resistance to Anti-PD-1 With Tumor Agnostic NBTXR3: From Bench to Bedside.

2021-11-01

Study of Novel Radioenhancer NBTXR3 Plus Radiotherapy in Patients With Locally Advanced Soft Tissue Sarcoma: Results of the Long-Term Evaluation in the Phase II/III Act.In.Sarc Trial.

2021-11-01

A phase I trial evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers.

Journal of Clinical Oncology2021-05-208 citations

Long-term evaluation of the novel radioenhancer NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma treated in the phase II/III Act.In.Sarc trial.

Journal of Clinical Oncology2021-05-203 citations

Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: From bench to bed side.

Journal of Clinical Oncology2021-05-202 citations

396 Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: from bench to bed side

Regular and Young Investigator Award Abstracts2020-11-011 citations

582 Modulation of TCR repertoire by radiotherapy-activated NBTXR3 nanoparticles

Regular and Young Investigator Award Abstracts2020-11-011 citations

410 Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers

Regular and Young Investigator Award Abstracts2020-11-01

Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy.

Journal of Clinical Oncology2020-05-203 citations

10 more papers not shown